[go: up one dir, main page]

NO20092586L - A-beta antistoff parenteral formulering - Google Patents

A-beta antistoff parenteral formulering

Info

Publication number
NO20092586L
NO20092586L NO20092586A NO20092586A NO20092586L NO 20092586 L NO20092586 L NO 20092586L NO 20092586 A NO20092586 A NO 20092586A NO 20092586 A NO20092586 A NO 20092586A NO 20092586 L NO20092586 L NO 20092586L
Authority
NO
Norway
Prior art keywords
parenteral formulation
beta antibody
beta
antibody parenteral
antibody
Prior art date
Application number
NO20092586A
Other languages
English (en)
Norwegian (no)
Inventor
Pierre Goldbach
Hanns-Christian Mahler
Robert Mueller
Christine Wurth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39190366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092586(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20092586L publication Critical patent/NO20092586L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20092586A 2006-12-11 2009-07-07 A-beta antistoff parenteral formulering NO20092586L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06025590 2006-12-11
PCT/EP2007/010825 WO2008071394A1 (en) 2006-12-11 2007-12-11 Abeta antibody parenteral formulation

Publications (1)

Publication Number Publication Date
NO20092586L true NO20092586L (no) 2009-07-17

Family

ID=39190366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092586A NO20092586L (no) 2006-12-11 2009-07-07 A-beta antistoff parenteral formulering

Country Status (21)

Country Link
US (1) US20110070225A1 (es)
EP (1) EP2094729A1 (es)
JP (1) JP2010512356A (es)
KR (1) KR20090104017A (es)
CN (1) CN101553504A (es)
AR (1) AR064220A1 (es)
AU (1) AU2007331712A1 (es)
BR (1) BRPI0721097A2 (es)
CA (1) CA2671968A1 (es)
CL (1) CL2007003583A1 (es)
CR (1) CR10823A (es)
EC (1) ECSP099403A (es)
IL (1) IL198963A0 (es)
MA (1) MA30975B1 (es)
MX (1) MX2009006199A (es)
NO (1) NO20092586L (es)
PE (1) PE20081477A1 (es)
RU (1) RU2009126420A (es)
TW (1) TW200831133A (es)
WO (1) WO2008071394A1 (es)
ZA (1) ZA200904014B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2006106903A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
EP2377886A1 (en) * 2005-12-12 2011-10-19 F. Hoffmann-La Roche AG Antibody glycosylation in the variable region
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
DK2238166T3 (da) 2007-10-05 2014-01-27 Ac Immune Sa Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme
US8524233B2 (en) 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof
KR20170116193A (ko) * 2008-06-20 2017-10-18 노파르티스 아게 응집이 감소된 면역글로불린
CA2736198A1 (en) * 2008-09-19 2010-03-25 F. Hoffmann-La Roche Ag Novel antibody formulation
WO2010056550A1 (en) 2008-10-29 2010-05-20 Wyeth Llc Methods for purification of single domain antigen binding molecules
KR101593285B1 (ko) * 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
BRPI0916072A2 (pt) * 2008-11-17 2015-11-10 Genentech Inc "uso de uma formulação, formulação farmacêutica, usos de um anticorpo 2h7 humanizado, método, método para aumentar a biodisponibilidade de um anticorpo e método de diálise in vitro"
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010100179A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
JP5896471B2 (ja) * 2009-11-20 2016-03-30 バイオコン リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 抗体製剤
CA2783715A1 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
EP2538973A2 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Stable antibody containing compositions
AU2011223710B2 (en) 2010-03-01 2016-04-14 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
EP2542579A1 (en) 2010-03-03 2013-01-09 Boehringer Ingelheim International GmbH Biparatopic abeta binding polypeptides
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012028683A1 (en) * 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
AU2012250872B2 (en) 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
HK1198689A1 (en) 2011-10-25 2015-05-29 Prothena Biosciences Limited Antibody formulations and methods
PL2822587T3 (pl) * 2012-03-08 2016-07-29 Hoffmann La Roche Preparat przeciwciała abeta
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN105025925A (zh) * 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 抗-催乳素受体抗体制剂
PT3024485T (pt) 2013-07-23 2021-01-25 Biocon Ltd Utilização de um parceiro de ligação de cd6 e método baseado no mesmo
EA201790914A1 (ru) 2014-10-24 2017-08-31 Мерк Шарп И Доум Корп. Коагонисты рецепторов глюкагона и glp-1
WO2016080367A1 (ja) * 2014-11-18 2016-05-26 塩野義製薬株式会社 安定化されたペプチド組成物
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN104946616A (zh) * 2015-05-12 2015-09-30 骏实生物科技(上海)有限公司 一种用于体外诊断试剂的通用固体稳定剂及其使用方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
UA123053C2 (uk) 2015-06-24 2021-02-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
HUE061985T2 (hu) * 2015-08-19 2023-09-28 Astrazeneca Ab Stabil IFNAR1-elleni készítmény
HK1255006A1 (zh) * 2015-09-22 2019-08-02 Pfizer Inc. 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂
MA43023A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN106620691B (zh) * 2015-11-04 2020-08-21 信达生物制药(苏州)有限公司 一种重组全人源抗ctla-4单克隆抗体制剂及其应用
AU2016380988B2 (en) 2015-12-30 2022-07-21 Genentech, Inc. Formulations with reduced degradation of polysorbate
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
CN106913869B (zh) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 一种抗ctla-4单克隆抗体制剂及其应用
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
SMT202300129T1 (it) * 2017-08-22 2023-05-12 Biogen Ma Inc Composizioni farmaceutiche contenenti anticorpi anti-beta amiloide
CN108373494A (zh) * 2018-02-27 2018-08-07 武汉伊艾博科技有限公司 一种防止重组蛋白质降解的保护技术
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂
CN112741804A (zh) * 2019-10-31 2021-05-04 上海君实生物医药科技股份有限公司 含有抗pd-l1抗体的稳定制剂
WO2021136274A1 (zh) * 2019-12-30 2021-07-08 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
US20230365667A1 (en) * 2020-09-30 2023-11-16 Merck Sharp & Dohme Llc Binding proteins and antigen binding fragments thereof that bind abeta
AU2024283314A1 (en) 2023-05-31 2025-11-13 F. Hoffmann-La Roche Ag Therapeutic use of bispecific anti-abeta/tfr antibodies
CN117088974B (zh) * 2023-08-14 2024-02-13 武汉健昊生物科技有限公司 一种抗体保存液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
HRP20050934B1 (hr) * 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
JP2008528638A (ja) * 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP2377886A1 (en) * 2005-12-12 2011-10-19 F. Hoffmann-La Roche AG Antibody glycosylation in the variable region
JP2009531371A (ja) * 2006-03-28 2009-09-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤

Also Published As

Publication number Publication date
KR20090104017A (ko) 2009-10-05
CR10823A (es) 2009-08-12
US20110070225A1 (en) 2011-03-24
ZA200904014B (en) 2010-04-28
PE20081477A1 (es) 2008-10-18
WO2008071394A1 (en) 2008-06-19
EP2094729A1 (en) 2009-09-02
BRPI0721097A2 (pt) 2014-07-01
ECSP099403A (es) 2009-07-31
RU2009126420A (ru) 2011-01-20
MX2009006199A (es) 2009-06-22
IL198963A0 (en) 2011-08-01
AR064220A1 (es) 2009-03-18
CL2007003583A1 (es) 2008-07-18
AU2007331712A1 (en) 2008-06-19
JP2010512356A (ja) 2010-04-22
AU2007331712A2 (en) 2009-07-30
TW200831133A (en) 2008-08-01
MA30975B1 (fr) 2009-12-01
CA2671968A1 (en) 2008-06-19
CN101553504A (zh) 2009-10-07

Similar Documents

Publication Publication Date Title
NO20092586L (no) A-beta antistoff parenteral formulering
Krauss et al. Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody
Brik et al. Sugar-assisted glycopeptide ligation
Renaudet et al. Chemoselectively template-assembled glycoconjugates as mimics for multivalent presentation of carbohydrates
Rich et al. Survey of the year 2007 commercial optical biosensor literature
Dudkin et al. Toward fully synthetic carbohydrate-based HIV antigen design: on the critical role of bivalency
Ni et al. Synthesis of maleimide-activated carbohydrates as chemoselective tags for site-specific glycosylation of peptides and proteins
AR054474A1 (es) Formulacion de anticuerpos estables
EA201290123A1 (ru) Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
TNSN07069A1 (en) Process for concentration of antibodies and therapeutic products thereof
WO2019170710A3 (en) Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
WO2007097923A3 (en) Method of constructing and screening libraries of peptide structures
WO2006016168A3 (en) Sialic acid derivatives
CN105324116B (zh) 调适具有聚脯氨酸支架的生物聚合物的多价相互作用
Li et al. Recognization of receptors on bone marrow-derived dendritic cells bound with Pholiota nameko polysaccharides
Okamoto et al. Efficient substitution reaction from cysteine to the serine residue of glycosylated polypeptide: repetitive peptide segment ligation strategy and the synthesis of glycosylated tetracontapeptide having acid labile sialyl-TN antigens
Niño-Ramírez et al. Evidence of isomerization in the michael-type thiol-maleimide addition: click reaction between L-cysteine and 6-maleimidehexanoic acid
WO2008028934A8 (en) Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
WO2012109383A3 (en) Method of determining protein binding characteristics of a drug candidate
Dong et al. Investigation of N-glycan functions in receptor for advanced glycation end products V domain through chemical glycoprotein synthesis
Li et al. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein
Rozbesky et al. Structural model of lymphocyte receptor NKR-P1C revealed by mass spectrometry and molecular modeling
Schenauer et al. An ion mobility–mass spectrometry investigation of monocyte chemoattractant protein-1
EP2423225A3 (en) NOGO-A binding molecules and pharmaceutical use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application